In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.
WIN 51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methylisoxazole), a new antipicornavirus drug, is a potent inhibitor of human entero- and rhinoviruses at concentrations not inhibitory to HeLa cell growth. In plaque reduction assays, WIN 51711 reduced plaque formation by 9 enteroviruses and 33 rhinoviruses, with MICs of 0.004 to 0.17 and 0.004 to 6.2 micrograms/ml, respectively. Addition of WIN 51711 to infected cells at concentrations of 0.02 to 5.0 micrograms/ml reduced the yield of picornaviruses by 90%. Other RNA viruses (nonpicornaviruses) and DNA viruses were unaffected by the compound.
Otto
M J
MJ
Fox
M P
MP
Fancher
M J
MJ
Kuhrt
M F
MF
Diana
G D
GD
McKinlay
M A
MA
D000998:Antiviral Agents / Q000494:pharmacology*; D003470:Culture Media; D004770:Enterovirus / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D010849:Picornaviridae / Q000187:drug effects*; D012229:Rhinovirus / Q000187:drug effects; D013997:Time Factors; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D003470:Culture Media; D007555:Isoxazoles; D010080:Oxazoles; C045978:disoxaril